Kolexia
Audemar Franck Gastro-entérologie
Audemar Franck
Gastro-entérologie
Centre Hospitalier de la Côte Basque
Bayonne, France
43 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Métastase tumorale Tumeurs du foie Tumeurs colorectales Carcinomes Cirrhose du foie Carcinome hépatocellulaire Fibrose Tumeurs du pancréas Hépatite

Collaborateurs

Voir plus
Nivet Dorothee
Nivet Dorothee
Centre Hospitalier de la Côte Basque, Bayonne, France
Oui Benoit
Oui Benoit
Centre Hospitalier de la Côte Basque, Bayonne, France
Guilngar Anne
Guilngar Anne
Centre Hospitalier de la Côte Basque, Bayonne, France
Khuong Huu Tam
Khuong Huu Tam
Centre Hospitalier de la Côte Basque, Bayonne, France

Industries

Voir plus
Ipsen
9 collaboration(s)
Dernière en 2022
Servier
8 collaboration(s)
Dernière en 2023
Merck-Serono
6 collaboration(s)
Dernière en 2023
MSD
6 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
POCHI: Pembrolizumab in Combination With Xelox Bevacizumab in Patients With Microsatellite Stable Mestatic Colorectal Cancer and a High Immune Infiltrate : a Proof of Concept Study
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
OSCAR: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
Hepatitis E Virus Infection in Patients with Chronic Inflammatory Bowel Disease Treated with Immunosuppressive Therapy.
Pathogens (Basel, Switzerland)   15 février 2023
Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort.
Cancer medicine   16 novembre 2022
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   11 janvier 2022
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
British journal of cancer   06 janvier 2022
SULTAN: A Randomized Phase II Study Comparing Treatment Intensification With CIAH Plus Systemic Chemotherapy to Systemic Chemotherapy Alone in Patients With Liver-only Colorectal Metastases Considered Still Non Resectable After at Least Two Months of Systemic Induction Chemotherapy
Essai Clinique (Unicancer)   03 janvier 2022
EQLVCPAL: Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy for Digestive Cancer
Essai Clinique (Centre Hospitalier de la Côte Basque)   27 octobre 2021
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.
Hepatology international   09 janvier 2021
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma.
Cancers   31 mai 2020